Revive Therapeutics

Pα+ Psychedelic Bulletin #150: Drug Development and Research UpdatesNovember 29, 2023
GH Research’s Lead 5-MeO-DMT Candidate Faces Development Hiccup • Psychae Therapeutics Scores AUD $4.5m to Develop DMT-Based Candidate • Cybin Closes $30m Offering • Grants Awarded to 8 ‘Young Investigators’ Exploring Psychedelics • atai Buys Out Remainder of DemeRx’s Ibogaine Asset; Announces Novel 5-HT2A Agonist Candidates • Compass Commences UK Portion of Phase 3 Trial, Officially Opens London Centre • Awakn Plans to Commence Enrollment for Phase 3 Study of Ketamine for Severe Alcohol Use Disorder in Q1 2024 • 14% of travellers are interested in a psychedelic retreat in 2024
Pα+ Psychedelic Patent Analysis (October 2023)November 24, 2023
This month: MindMed scores psilocybin-antidepressant co-treatment patent • A spate of PCTs published from GH Research • Early fruits of Cybin's Small Pharma acquisition • and more...
Pα+ Mini Interview with Ester Kincová and Steve Rolles: Regulating the Non-Medical Use of PsychedelicsNovember 20, 2023
We spoke to Ester Kincová and Steve Rolles from Transform Policy Foundation, co-authors of a new publication, 'How to Regulate Psychedelics'. We sought to better understand their perspectives on emergent international psychedelic policy ‘experiments’ and broader contexts.
Pα+ Mini Interview with Eddie Jacobs: Post-Trial Provisions in Clinical Psychedelic ResearchNovember 20, 2023
Earlier this month Eddie Jacobs et al. published an article in Neuroethics titled, When the Trial Ends: The Case for Post-Trial Provisions in Clinical Psychedelic Research. We asked Jacobs a few questions about the current and potential state of post-clinical-trial support.
Pα+ Psychedelic Bulletin #149: Worldwide Psychedelic Policy DevelopmentsNovember 17, 2023
TREAT Retreats • Wiener Regroups: Decrim. Off the Agenda • California Psilocybin Decrim. Initiative Continues Signature Gathering • Veterans’ Affairs Subcommittee on Health Discusses Psychedelics • Canadian Senate Subcommittee on Veterans Affairs: “The Time is Now” to Fund Psychedelic Research • Transform Publishes “Practical Guide” to Regulating Psychedelics • UK Government Responds to Drugs Committee’s Report • Other Policy-Related News

Revive Therapeutics

Latest News

Revive Therapeutics Announces Initiation of Novel Bucillamine Formulation Development

Revive Therapeutics Announces Filing of Patent for Bucillamine in the Treatment of Exposure to Chemical Warfare Agents

Revive Therapeutics Announces Results of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19

Revive Therapeutics Announces Data Safety Monitoring Board Meeting Date on Phase 3 Clinical Study of Bucillamine in the Treatment of COVID-19

Revive Therapeutics Advances MDMA Transdermal Patch Development with Purchase of MDMA Supply from PharmAla Biotech

Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder

Join our Newsletter

Psychedelic Alpha

Quick Links

Newsletter

Join Our Newsletter

Subscribe to Pα+

Consider subscribing Pα+ for exclusive insights, interviews and analysis.

No thanks, continue to site.